Information Provided By: 
Fly News Breaks for October 29, 2019
KURA
Oct 29, 2019 | 15:26 EDT
After Kura Oncology presented updated data on its ongoing Phase 2 RUNHN trial evaluating tipifarnib, Piper Jaffray analyst Tyler Van Buren said the results boost his conviction in the ongoing registrational AIM-HN trial, which he views as "highly likely to succeed." Van Buren, who projects HRAS mutant head and neck squamous cell carcinomas as a potential global sales opportunity of over $500M, reiterates an Overweight rating on Kura shares.
News For KURA From the Last 2 Days
There are no results for your query KURA
